Synchronized and controlled release of metformin hydrochloride/glipizide from elementary osmotic delivery.
The combination of metformin hydrochloride (MTF) and glipizide (GLZ) is second-line medication for diabetes mellitus type 2 (DMT2). In the present study, elementary osmotic pump ( EOP) tablet is designed to deliver the combination of MTF and GLZ in a sustained and synchronized manner. By analyzing different variables of the formulation, sodium hydrogen carbonate is introduced as pH modifier to improve the release of GLZ, while ethyl cellulose acts as release retardant to reduce the burst release phase of MTF. A two-factor, three-level face-centered central composite design (FCCD) is applied to investigate the impact of different factors on drug release profile. Compared with conventional tablets, the EOP tablet demonstrates a controlled release behavior with relative bioavailability of 99.2% for MTF and 99.3% for GLZ. Data also shows EOP tablet is able to release MTF and GLZ in a synchronized and sustained manner both in vitro and in vivo.
['Pan|Hao|H|', 'Jing|Hengpan|H|', 'Yang|Xinggang|X|', 'Pan|Weisan|W|', 'Chen|Tianbao|T|']
D001682:Biological Availability D002482:Cellulose D002626:Chemistry, Pharmaceutical D003692:Delayed-Action Preparations D016503:Drug Delivery Systems D005913:Glipizide D007004:Hypoglycemic Agents D008687:Metformin D009995:Osmosis D012995:Solubility D013607:Tablets
metformin hydrochloride/glipizide Elementary osmotic pump (EOP) face-centered central composite design synchronized and sustained release